Author: Zhuifeng Guo, Xuwei Lu, Fan Yang, Liang Qin, Ning Yang, Jiawen Wu and Hang Wang

Docetaxel chemotherapy plus androgen-deprivation therapy in high-volume disease metastatic hormone-sensitive prostate cancer in Chinese patients: an efficacy and safety analysis – European Journal of Medical Research

Most patients with metastatic prostate cancer (mPC) initially responded positively to androgen suppression, however, invariably became resistant to hormone manipulation after 18–24 months from treatment [10]. Therefore, it is important to…